Recent

% | $
Quotes you view appear here for quick access.

P L C SYSTEMS AŞ Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • i_hate_hillsamuel i_hate_hillsamuel May 29, 2009 8:27 AM Flag

    w/plc saying renal guard has the potential of $500 in rev's

    "why did edward's sell there right's to novadaq to market plc USA business ? "

    Because they were not making any money and knew they never would. It was a diversion from there core competencies.

    "why does novadaq ceo think spyimaging will enhance tmr procedure ?"

    Because he will say anything to keep his struggling business afloat. Like saying he could market TMR, when they can barely market there own product.

    "why does edward's still own 5.3 million share's of plc ?"

    Why not? It's a drop in the bucket for a company the size of EW. Who would buy them if they wanted to sell???

    Now I have some questions for you Scom.

    Why would Edwards buy back in to a business they already divested from.?

    Why would Edwards enter a Renal market that they had no experience in and was a complete departure from there core cardiovascular focus.?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Hill, good points, indeed. Couldn't have said them better myself.
      However, as for Novadaq, I think you can be more acknowledging that Novadaq *did* (and probably *does*) think that TMR would be helpful for some patients, and that in tandem with Spy, patients and surgeons might find it useful, beneficial, and reasonable, and economic treatment possibility. I don't think you need to inpugn the integrity of Nova's CEO or to question the reality and possibilities of their plans and hopes.
      Nevertheless, the market for TMR remains limited, there's competition for a company that *concentrates* on it and its further development and applications, and, as PLC notes, the recession and financial difficulties means for most hospitals a limit, if not a diminishment, of their interest or purchase of new lasers, etc.
      Also, Hill, as you know, I have more hope in PLC's turnaround and have appreciation for how they've conducted their Renal Guard development, and think there *is* potential for continued stock price appreciation (rebound), etc., than do you.
      Other than those points, excellent response to Scom's unfortunate repetitive fantasies about what TMR can achieve for PLC (which is not to say that there are not areas in intl. sales as well as domestic market that might allow for varying, occasional quarterly increases of TMR revenues).

      • 2 Replies to participant42
      • I didn't really mean to question the integrity of the CEO. I'm sure he is well intentioned and perhaps TMR/SPY is worthwhile and a good business fit. I just feel that Novadaq was not up to the task of supporting the venture despite the good intentions. I have not lost all hope for PLC, but after many disappointments, they need to show me something, before I shower them with any praise.

      • the lasers are placed and increasing kit sales is the key in the USA,169 LASERS PLACED IN THE USA,ONE TMR PER WEEK PER HOSPITAL W/LASER = 8,788K KIT SALES PER YEAR AND THAT JUST PUT'S A DENT IN THE PATIENT'S PER YEAR THAT COULD BE A POTENTIAL CANDIDATE FOR TMR............BUT REALLY WHY CARE SO MUCH WHAT I SAY ?

    • edward's sold the right's to novadaq for a nice price and it is only for a period of time but not sure who would have the right's to market tmr after novadaq time expires,it's less than 4 years i think...........ever think edward's,plc,novadaq wanted tmr and spy combined,i mean even build a tmr laser w/spy attached...........edward's is in the cath business and in the heart biz,renal guard is both..................unedited

 
PLCSF
0.00(0.00%)